Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The litigation centers on claims that ADMA Biologics masked a channel stuffing scheme and failed to disclose related-party transactions involving Genesis BioPharma Services, an entity allegedly operating from the company's Ramsey, New Jersey headquarters. While management repeatedly certified that their disclosure controls were effective, the complaint contends these assertions were materially false. Specifically, the lawsuit claims the company shipped unwanted quantities of its specialty product, ASCENIV, to distributors to artificially inflate revenue figures.

A March 2026 research report acted as a catalyst for the action, estimating that the company’s reported 20% revenue growth was actually a 3% contraction. This revelation coincided with the abrupt resignation of the company's CFO in February 2026. Attorneys at Levi & Korsinsky, LLP, who are representing the class, argue that effective internal oversight would have captured these transactions and prevented the alleged misrepresentations. Investors seeking to participate in the recovery process are encouraged to gather brokerage records documenting their transactions during the defined class period.